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5Introductory note and acknowledgements
In-depth reviews of topical interest are published as Selected issues each year. These reports are based on information 
provided to the EMCDDA by the EU Member States and candidate countries and Norway as part of the national reporting 
process.
The most recent Selected issues are:
Mortality related to drug use in Europe: public health implications;
•  Guidelines for the treatment of drug dependence: a European perspective;
•  Cost and financing of drug treatment services in Europe: an exploratory study;
•  Treatment and care for older drug users;
•  Problem amphetamine and methamphetamine use in Europe;
•  Trends in injecting drug use in Europe.
All Selected issues (in English) and summaries (in up to 23 languages) are available on the EMCDDA website: 
http://www.emcdda.europa.eu/publications/selected-issues
The EMCDDA would like to thank the following for their help in producing this Selected issue:
•  the heads of Reitox national focal points, their staff and the national experts on drug-related deaths;
•  the services within each Member State that collected the raw data;
•  the members of the Management Board and the Scientific Committee of the EMCDDA;
•  the Publications Office of the European Union.
Reitox national focal points
Reitox is the European information network on drugs and drug addiction. The network is comprised of national focal points in the EU 
Member States, Norway and the candidate countries and at the European Commission. Under the responsibility of their 
governments, the focal points are the national authorities providing drug information to the EMCDDA.
The contact details of the national focal points may be found at: 
http://www.emcdda.europa.eu/about/partners/reitox-network

7Most drug users are young adults of childbearing age. Indeed, 
treatment data indicates that almost one in ten of all clients 
entering treatment live with at least one child. Furthermore, the 
number of drug users entering treatment who report living with 
children has been increasing over the last five years. The risks 
of using drugs during pregnancy have been well documented, 
and the harms related to drug use in families with children are 
well known. However, not all pregnant women who use drugs 
have problems during or after their pregnancies, and not all 
parents with drug problems have difficulty caring for their 
children. Still, a common and often well-founded concern of 
drug-using parents is that they are inevitably viewed as 
neglectful and their children will be taken away from them. 
There are, however, an array of programmes to help both 
pregnant drug users and drug-using parents. To date, though, 
no comprehensive information has been available on the 
extent of these problems in Europe, and how they are 
responded to at European level.
The objective of this Selected issue, therefore, is to provide a 
European overview of the available responses (interventions, 
laws and policies) to these problems, along with a 
description of available European studies on the risks of 
drug use during pregnancy and for drug-using parents and 
their children. The information presented here is based on a 
dedicated data collection exercise that was carried out in 
23 European countries (see Figure 1) through the Reitox 
network of national focal points, supplemented by data 
routinely collected by the EMCDDA through the Exchange 
on Drug Demand Reduction Action (EDDRA). This 
information varied in scope and depth, with several 
countries reporting extensively on a wide range of 
interventions available to help families affected by drugs, 
while other countries were able to provide only limited 
amounts of information owing to a lack of specific 
responses, for example, or because these target populations 
are addressed by general services only. Much of the 
information presented in this report is based on publications 
in the national languages of the reporting countries, and on 
data that were specifically reported by countries for this 
publication and therefore may be unavailable in this format 
anywhere else. Information presented here reflects the 
presence of responses and not necessarily the extent of 
coverage or the effectiveness or evidence base of these 
interventions. The systematic assessment of the evidence 
base of interventions and the evaluation of their impact are 
important tasks, but are outside the scope of this publication. 
Based on the input from the responding countries, this 
Selected issue provides a broad overview, with examples 
drawn from a wide range of European countries, and 
constitutes a comprehensive picture of what Member States 
have done to help these vulnerable populations.
The first section of the publication deals with pregnant drug 
users, and the second section describes the situation 
regarding drug-using parents and their children. Both 
sections first describe studies reported by the national focal 
points on the harms of drug use, and then continue by 
delineating available responses (including prevention, harm 
reduction, treatment, law and policies). There is often an 
overlap in responses: in many cases, multidisciplinary care 
is available from the beginning of pregnancy through early, 
and in some cases late, childhood; and law and policies 
sometimes make no distinction between pregnant drug users 
and drug-using parents, but consider the interest of the child, 
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Figure 1: Countries covered in this publication
8Data on the prevalence of drug use among pregnant women 
are not available for most European countries. Where 
information is available, it often comes from isolated studies 
using various methodologies, and the results are not readily 
comparable. A study conducted in an inner-city maternity 
hospital in Dublin, Ireland, in 1992, for example, found that 
4% of antenatal and 6% of postnatal women tested positive 
for drug metabolites. In a recent study, also using biological 
specimens, hair analysis showed that 16% of mothers giving 
birth in an Ibiza hospital had used illicit drugs during the 
third trimester of their pregnancy (Friguls et al., 2012), 
although only 2% of mothers reported drug use during their 
pregnancy. In Latvia, mothers reported drug use in 0.2% of 
live births and 0.8% of stillbirths. The National Registry of 
Mothers at Childbirth in the Czech Republic reported a 
prevalence of 1.8% of illicit drug use among over 1 million 
mothers between 2000 and 2009.
The true prevalence of drug use among pregnant women, 
however, is difficult to ascertain, and differences across 
countries or in certain areas may also exist. Ireland, for 
example, reported that the proportion of urine samples that 
tested positive for drug metabolites was higher among 
women admitted for labour than among women attending 
scheduled antenatal visits. One reason for this may be that 
women who use drugs are less likely to receive antenatal care 
than women who are drug free. In Latvia, for example, 
antenatal care is received before the 12th week of pregnancy 
by 90% of expectant women in the general population, 
compared with 70% of those who had ever used drugs.
Risks of drug use during pregnancy
All psychoactive drugs, including alcohol, tobacco and 
some prescribed medications, may have adverse effects on 
the pregnancy, the unborn child and the newborn. Different 
drugs, however, may act differently (Table 1). This may be a 
result of not only to the drug itself, but also the poor overall 
health and the nutritional status of the drug-using expectant 
Pregnant drug users
Table 1: Health harms associated with substance use during pregnancy
Alcohol Tobacco Cannabis Amphetamines Cocaine Opioids
Low birth weight + + + + +
Miscarriage + + + + +
Perinatal mortality + + + (a)
Developmental problems in childhood + + +
Foetal morbidity + + + +
Premature birth + + +
Decreased foetal growth +
Impaired intrauterine growth + +
Neonatal withdrawal symptoms + +
Premature rupture of membranes, placental abruption + +
Preterm delivery +
Respiratory depression +
(a) Related to withdrawal.
NB:  The effect of these drugs may be confounded by polydrug use and/or other health and lifestyle factors associated with drug use.
Source:  A summary of the health harms of drugs, The Centre for Public Health, Faculty of Health & Applied Social Science, Liverpool John Moore’s University, 
on behalf of the Department of Health and National Treatment Agency for Substance Misuse (2011).
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mother. The degree of the impact of drug use during 
pregnancy largely depends on the intensity of drug use.
Several studies in the Netherlands have assessed the 
short- and long-term effects of cannabis use during 
pregnancy. Short-term effects included reduced foetal 
growth, smaller foetal head size, reductions in the foetal 
placental and cardiac blood flow, and low birth weight (El 
Marroun et al., 2009). The effect of cannabis (usually 
combined with tobacco) on intrauterine growth seemed 
stronger than that of antenatal tobacco exposure alone, 
and heavier use was associated with increased harm (El 
Marroun et al., 2010). At the age of 18 months, girls – but 
not boys – who were exposed to cannabis or tobacco in 
the womb showed increased aggression and attention 
problems, although the latter association disappeared 
when controlled for confounders (El Marroun et al., 2011). 
As the child grows older, however, these effects may 
disappear.
The vasoconstrictive effect of cocaine and amphetamines, as 
described by studies in the national reports of Belgium and 
Germany, decreases the blood supply in the area of the 
placenta in pregnant women using these drugs. This may 
result in miscarriage during the first trimester of pregnancy, 
and placental abruption, intrauterine death and premature 
birth in the third trimester. In addition, retarded foetal growth 
and reduced head circumference were also observed. While 
during the first two years of the child no further teratogenic 
effects (1) were described, some studies found an increased 
incidence of sudden infant deaths and certain behavioural 
disorders.
Results of research conducted in Germany and Austria 
indicate that the teratogenic effects of opioids are fewer 
than, for example, those of alcohol or tobacco. Anomalies 
during pregnancy and at birth include insufficient foetal 
growth and intrauterine development of the bones, 
intrauterine death, premature birth, anomalies in 
spontaneous movements, and neonatal withdrawal 
syndrome. One study in Vienna found prenatal dystrophy 
and microcephaly in 21% and 14%, respectively, of 
newborns of women who used heroin during their 
pregnancies. During the first year of life, elevated risks of 
sudden infant death and delayed statomotoric development 
have been observed. In some children, microcephaly at birth 
remained later on in life, resulting in mild cognitive 
impairment. A range of eye problems, including strabismus, 
have been reported by studies in the United Kingdom 
among children who had been exposed to opioids in the 
womb.
Injecting drug users have a higher than average prevalence 
of blood-borne infectious diseases, and these can be 
transmitted to the fetus (Gyarmathy et al., 2009). The most 
common blood-borne infection among injecting drug users is 
hepatitis C, the transmission of which during birth varies 
depending on a number of factors. Available evidence 
suggests that mother-to-child transmission of the hepatitis C 
virus (HCV) occurs only during pregnancy and birth, but not 
through breastfeeding. A systematic review of worldwide 
transmission rates found that transmission of HCV from 
mother to child depends largely on the presence in the 
mother’s blood of viral RNA and whether the mother is 
co-infected with human immunodeficiency virus (HIV) 
(Thomas et al., 1998). Among those who are uninfected with 
HIV, the probability of transmission is 1–3% among HCV 
RNA-negative and 4–6% among HCV RNA-positive women. 
Among those infected with both HCV and HIV, the 
probability of HCV transmission can be as high as 41%, and 
that of HIV is also high.
Responses to drug use among pregnant 
women
Interventions involving pregnant drug users include 
substance use treatment and antenatal and postnatal 
programmes. Substitution treatment for drug use during 
pregnancy, however, is available only for opioid users, with 
the aim to stabilise the users’ lifestyle and encourage them to 
(1) Effects that cause developmental malformations in the foetus or later on in the life of the newborn.
Neonatal abstinence syndrome
The use of cocaine, opioids and potentially other drugs 
during pregnancy may lead to withdrawal symptoms in the 
newborn. Neonatal withdrawal, also referred to as 
neonatal abstinence syndrome, is characterised by signs of 
hyper-irritability of the central nervous system, 
gastrointestinal dysfunction, impaired breathing and 
generalised symptoms such as yawning, sneezing and 
fever. Studies in the United Kingdom have found overall 
neonatal abstinence syndrome rates as high as 68% among 
the newborns of opioid-using mothers, with a dose–
response relationship between maternal drug use and the 
development of the syndrome (Scottish Executive, 2006). In 
these studies, about half of the babies who were initially 
asymptomatic developed delayed onset neonatal 
abstinence syndrome, and, while many of the babies who 
received treatment were well by age 20 weeks, about a 
quarter required long-term follow-up and care.
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use antenatal and obstetric services. Antenatal care reduces 
the complications of pregnancy and birth – especially those 
related to neonatal withdrawal – and decreases the 
probability of birth defects.
Drug treatment
Many opioid users want to cease using the drug when they 
find out that they are pregnant, but opioid withdrawal is a 
high-risk option because a return to heroin use during 
pregnancy can result in poorer obstetric outcomes, and 
severe opioid withdrawal symptoms may induce spontaneous 
abortion in the first trimester of pregnancy, or premature 
labour in the third trimester (WHO, 2009). Therefore, 
opioid-dependent pregnant women are encouraged to start 
opioid substitution treatment and those who are already 
receiving this treatment are advised to continue.
A drug liaison midwife service was initiated in 1999 in each 
of Dublin’s three maternity hospitals to ensure that pregnant 
opioid users engage in antenatal and drug services, and 
that they are stabilised on methadone. A preliminary 
assessment allows immediate admission to treatment. The 
mainstay of treatment is opioid substitution with methadone: 
stabilisation of drug use is emphasised, and women are 
encouraged to remain on oral methadone throughout their 
pregnancy. The option to detoxify after the first trimester 
exists, but women are not pressured to reduce dose or to 
detoxify. Those who had difficulties stabilising are offered 
inpatient admission to a specialist drug dependency unit. A 
fast-track system to admit pregnant women into treatment is 
provided in the United Kingdom, where substitute 
prescribing can ‘occur at any time in pregnancy’ as it is less 
risky than continued drug use.
Guidelines and quality assurance of services for 
pregnant drug users
Substitution treatment combined with social work and addiction 
counselling is the standard practice for treatment of heroin use 
during pregnancy (Mactier, 2011). Methadone is the most 
commonly available and prescribed opioid substitution 
medication in Europe, although, in countries where they are 
available, buprenorphine and slow-release oral morphine may 
also be prescribed. In a number of countries methadone is 
reported as the primary substitution medication (e.g. Germany, 
Ireland, Latvia, the Netherlands, the United Kingdom), whereas 
in some others buprenorphine is the first-choice medication 
(e.g. Estonia, Norway). In Germany, in addition to the 
substitution medications commonly prescribed for opioid-using 
pregnant women, treatment with diamorphine is also available 
– though only for high-risk individuals, under strictly controlled 
circumstances.
Recommendations follow international standards, and in some 
countries pregnant women receive priority in treatment entry. 
Treatment protocols for opioid-using pregnant women, however, 
may vary by country. In many countries, substitution treatment is 
encouraged at any time during the pregnancy, while 
detoxification is strongly discouraged; especially during the first 
trimester, to prevent birth defects and miscarriage, and the third 
trimester to prevent premature birth.
Guidelines for services for pregnant drug users and their 
newborn were reported by eight countries, while one country 
(Portugal) reported that guidelines are being developed. The 
majority of these guidelines address substitution treatment. In 
Germany, Ireland, Romania and the United Kingdom, guidance 
is provided within the general framework for substitution 
treatment, with pregnant women as a specific subgroup, while 
Hungary, Norway and Sweden have developed special 
guidelines.
Three countries (Ireland, the Netherlands, Romania) reported 
quality assurance documents addressing neonatal abstinence 
syndrome. In the Netherlands, two specific protocols are 
available concerning diagnostics, medical treatment, support 
and multidisciplinary treatment or care of both child and 
parents. In Ireland, the Irish Prison Service’s healthcare 
standards provide guidance on medical treatment, 
breastfeeding and psychosocial support. Finally, in Romania, 
within the general framework of clinical guidelines for opioid 
substitution treatment, recommendations are provided on 
treatment choices and on breastfeeding for infants with 
neonatal abstinence syndrome.
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Multidisciplinary comprehensive antenatal and 
postnatal programmes
Several countries reported multidisciplinary comprehensive 
care programmes (2). Doctors, psychologists and social 
workers follow up drug-using women and their children from 
early pregnancy into childhood to ensure the well-being and 
healthy development of the mother and the child. The family 
outpatient centre of Hvidovre Hospital in Denmark is a 
specialised unit for pregnant women who use or have used 
drugs and families with drug problems (where, for example, 
the father or family members other than the mother use 
drugs). Children born to these mothers are followed up with 
comprehensive medical and psychological care until they 
reach school age. Based on this model, the Danish 
government has established and funded family outpatient 
centres throughout the country to help pregnant drug users 
and children from birth up to school age who were exposed 
to drugs in the womb. The Danish focal point reported that 
the occurrence of pregnancy and birth complications and 
birth defects among drug-using pregnant clients decreased 
considerably in the country as a result of comprehensive 
antenatal and postnatal care programmes.
Some of these care services, such as Benniena in Malta, 
grew over a decade from a consulting service for pregnant 
drug users to a comprehensive centre for families affected by 
drug use. Malta responded to the increasing number of 
pregnant drug users with the creation of a working 
committee on ‘substance abuse mothers’, composed of a 
multidisciplinary panel including social workers, 
paediatricians, midwives from all obstetrics wards, paediatric 
nursing officers, antenatal midwives and medical doctors. 
The remit of the working committee is to follow mothers-to-be 
who have substance use problems and to ensure that drastic 
measures, such as care/court orders, can be avoided, and 
the child is placed within the family of birth if possible.
The HAL (‘drugs, alcohol and pharmaceuticals’) services in 
Finland form a multiprofessional treatment model, whereby a 
network of maternity outpatient clinics – covering the entire 
country – provides psychosocial approaches with 
comprehensive medical care. Two-thirds of HAL clients are 
referred from maternity clinics and the rest from substance-
use or other services, such as emergency outpatient clinics. 
All university hospitals have HAL services, which treat a total 
of about 400 substance-using mothers each year, providing 
pregnancy monitoring (including repeated alcohol and drug 
tests and laboratory tests relevant for at-risk groups, such as 
hepatitis B, hepatitis C and HIV), psychiatric and 
psychological assistance, and paediatric assistance. 
Children born in the HAL system are followed up regularly 
with health appointments and visits and by child welfare 
services until they reach school age. Low-threshold agencies 
called ‘family ambulatories’ have been established in 
Norway based on a Danish model, providing – in 
collaboration with postnatal wards, mental healthcare 
services and various municipal agencies – preventative 
health assistance to pregnant substance users and follow-ups 
of their children until they reach school age.
The ‘addictology mobile team’ of the Port Royal-Cochin 
hospital group in Paris, France, aims to help pregnant drug 
(2)  In addition to the examples presented in this section, the provision of multidisciplinary comprehensive care was also reported by Belgium, Luxembourg and 
the United Kingdom.
Neonatal withdrawal among newborns of 
women in substitution treatment
While methadone is the most commonly prescribed 
substitution medication in Europe, its side-effects commonly 
include neonatal withdrawal. In a study among mothers 
who received methadone at delivery, neonatal abstinence 
syndrome occurred in 28% of infants delivered to women 
receiving low doses (5–30 mg), rising to 43% for those on 
medium doses (31–50 mg) and 71% for high doses 
(51–95 mg) (Scully et al., 2004). Other studies have 
confirmed the link between maternal methadone exposure 
and the incidence of neonatal abstinence syndrome among 
newborns (Binder and Vavrinkova, 2008; Cleary et al., 
2011). Given the high rates of neonatal abstinence 
syndrome among the newborns of women receiving 
methadone while pregnant, other substitution treatments are 
of great interest. In a study in which pregnant opioid users 
received oral methadone, buprenorphine or slow-release 
morphine, 40% of all newborns did not require treatment 
for neonatal withdrawal because they showed no or only 
mild symptoms (Ebner et al., 2007). However, 79% of 
newborns whose mother received buprenorphine, 
compared with 32% in the methadone group and 18% in 
the morphine group, did not need neonatal abstinence 
syndrome treatment. Another study also found that babies 
who were exposed to buprenorphine in the womb had 
shorter hospital stays and shorter durations of treatment for 
neonatal abstinence syndrome, with significantly smaller 
doses of morphine, than babies who were exposed to 
methadone before birth (Jones et al., 2010). While more 
research is needed to confirm these results, many authors 
recommend treating opioid-dependent pregnant women 
with buprenorphine instead of methadone (Binder and 
Vavrinkova, 2008; Kakko et al., 2008).
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users to gain or regain parenting abilities. The team, which 
provides assistance during pregnancy and child birth, and 
in the postpartum period, consists of five professionals: a 
psychiatrist and a general practitioner (both specialised in 
drug addiction), a social worker, a nurse and a midwife. 
Since 2010, 35 projects to support the well-being of 
drug-using mothers, mothers-to-be and their young or unborn 
children have been initiated in France. The projects bring 
together specialised drug treatment centres, mainstream 
housing and social reinsertion facilities and low-threshold 
services, in collaboration with maternity clinics, emergency 
ward and infant early sociomedical welfare system 
(including psychiatry).
Several hospitals in Austria (especially in Vienna and 
Innsbruck) offer a combination of antenatal and postnatal 
medical, psychosocial and welfare services for this 
population. After a one-year pilot project, a programme 
initiated in 2010 at the University Hospital of Psychiatry in 
Innsbruck consisting of scheduled examinations and 
assistance by a midwife is available to pregnant women, 
who receive opioid substitution treatment and additional 
services by the addiction clinic. Many hospitals in Vienna 
offer comprehensive care, including outreach activities to 
contact women at an early stage of their pregnancy. For 
example, the Comprehensive Care Project at the University 
Hospital in Vienna is characterised by a multiprofessional 
approach including physicians, social workers, pharmacists, 
nurses and psychotherapists, providing both antenatal care 
and aftercare of the children. Expectant mothers receive 
psychiatric and psychosocial care, and maintenance therapy 
with methadone, morphine or buprenorphine. Newborns 
with withdrawal syndrome receive immediate treatment, and 
all children are followed up until age six with regular 
checkups, and receive therapy (e.g. physiotherapy or 
speech therapy) when needed. The project has also 
generated a wealth of longitudinal scientific information on 
pregnant drug users and their developing children.
In the Netherlands, the Precaution (Voorzorg) programme 
was developed based on the American Nurse Family 
Partnership, a project that had been found effective in 
several randomised controlled trials, and adapted to the 
Dutch situation. The project follows a standardised protocol, 
and targets drug-using women under the age of 25 who 
have no other children, and who are at most 28 weeks 
pregnant, and follows them up until the child is two years 
old. During this period, participating families receive 60 
home visits lasting 60–90 minutes, with a decreasing 
frequency from once a week after birth to once a month at 
Prevention of vertical infection among newborns 
of infected mothers
Compared with HIV infection, no effective and safe method 
exists to prevent HCV infection from being passed on from 
the mother to her newborn, although anti-HIV therapy in co-
infected women has been shown to somewhat reduce the 
transmission probability of both viruses (Gyarmathy et al., 
2009). Among women infected with HIV only, the 
transmission through breast milk, during pregnancy and 
during birth can be reduced to less than 1% with early 
diagnosis and effective treatment of the mother. The 
mother-to-child transmission of hepatitis B virus (HBV), 
another infection common among drug users, can be 
prevented by a combination of anti-HBV immunoglobulin 
and a series of HBV vaccines. There are also indications 
that sexually transmitted bacterial infections, such as 
chlamydia, syphilis and gonorrhoea, can be successfully 
treated with antibiotics, and this treatment also prevents 
vertical transmission.
Special concerns and populations
One particular concern is drug-using new mothers 
disappearing and leaving their newborns in the hospital 
soon after giving birth, often without even naming them. 
The Bulgarian focal point, for example, reported this 
practice, especially among young Roma drug-using 
women. As a response, the non-governmental organisation 
‘For Our Children’ visits the Plovdiv General Hospital for 
Active Treatment – where many of these abandonment 
cases have been reported – and provides emotional, 
psychological and social support and counselling to 
birthing women who may be at such risk. The organisation 
aims to promote reintegration of babies into their biological 
families, or, if that is not possible, to support alternative 
families, especially those next of kin. Additional assistance 
to pregnant or birthing drug-using women includes the 
provision of food and items for the baby, such as nappies, 
bath lotions and clothes.
A special population among pregnant drug users is those in 
prison. Comprehensive antenatal services exist, for 
example, in Mountjoy Prison in Dublin, Ireland, where 
antenatal care including HIV testing and, if they are 
infected, treatment is offered to expecting mothers. These 
services collaborate closely with community organisations to 
prepare the mother and her newborn for their eventual life 
outside prison. Another special population is women with 
HIV, an infection often related to drug injecting; in Estonia, 
to prevent transmission through breast feeding, infants of 
HIV-infected women have the opportunity to obtain formula 
milk for free until the child reaches the age of 12 months.
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the end of the project. The Red Cross Assistance in Spain 
runs a follow-up programme for high-risk pregnant women, 
with the goal of reducing the harmful effect of their drug 
consumption on their lives and on the lives of their 
newborns. In this project, pregnancy is considered an 
opportunity to initiate medical follow-up and addiction 
treatment, including substitution therapy, infection control or 
psychiatric care, if needed.
A large variety of multidisciplinary comprehensive 
programmes are available in Germany at local, regional 
and national levels. The WIGWAM outreach programme in 
Berlin, for example, is an interdisciplinary cooperation 
available for pregnant drug users since 1987. In addition to 
antenatal care, medical help related to birthing, and 
addiction treatment (including inpatient treatment for 
newborns with neonatal abstinence syndrome), women are 
offered referrals to substitution treatment, psychosocial 
assistance, home visits and welfare services. The Early 
Intervention for Pregnant Women with Substance Addictions 
(Fruehintervention fuer suchtmittelabhaengige Schwangere, 
KIDS) was initiated in Kassel in 2007 with the objective of 
reaching pregnant women who have substance addictions 
as early as possible in pregnancy in order to provide 
referrals to medical and social services. In Portugal, the 
Integrated Project of Maternal Support provides integrated 
and global care to pregnant and postpartum addicted 
woman and their children, following outpatient therapeutic 
modalities best suited to each situation regarding the 
treatment, harm-reduction and reintegration needs of these 
patients.
Policy and legal frameworks concerning 
pregnant drug users
In terms of legislation applying to pregnant users, or to 
children before birth, it can be seen that in some Member 
States pregnancy is one criterion that may trigger eligibility 
or facilitate an application for opioid substitution 
treatment (3). Treatment is based on the mother’s consent; 
Finland and Sweden reported that it was difficult legally to 
protect a fetus, for example by compelling the mother to 
submit to care, as rights started at birth, and the right of the 
mother to self-determination would be violated, though in 
both countries there have recently been proposals to change 
this. In the Netherlands, coercive treatment in the form of a 
prenatal supervision order is possible once a pregnancy has 
attained 24 weeks. It is also possible to enforce psychiatric 
hospital admission for pregnant drug users, but this is 
seldom applied, as that law was designed to address mental 
health issues. However, one of the key legal issues with this 
topic is the clashes of laws and/or perceptions of them: 
jeopardising the well-being of the child by lifestyle conflicts 
with the right of a parent to raise children. While a mother 
may have the right to protection or assistance, and the 
examples mentioned above show how she may be 
encouraged to take it, she may also fear applying for it if 
there is a risk that her child would be taken away, and may 
even hide or deny her pregnancy because of this; this was 
reported as a known concern by Germany, Hungary, the 
Netherlands and Sweden.
While various countries establish obligations to report 
matters that concern child welfare, it was not clear how 
many would extend this obligation to concern for the 
welfare of an unborn child. Sweden reported that the 
obligation did not apply to unborn children, whereas in 
Finland, since March 2010, an anticipatory child welfare 
notification must be submitted when there is reasonable 
cause to suspect that an unborn child will need child welfare 
support measures immediately after birth. In Denmark, 
concerns about the welfare of unborn children must also be 
reported, and the obligation to report child abuse applies to 
all citizens regardless of their relationship to the child. In the 
United Kingdom (England and Wales), there are no 
mandatory reporting obligations, but professionals and local 
authorities have a duty to report if an unborn baby or a 
child is at risk of significant harm. In most countries, 
obligations to report (or act on) suspicions of a child ‘in 
trouble’ are placed mainly on professionals, for example 
members of the social service system (Slovenia), members of 
the child risk-warning system (Hungary) and those who work 
with children (Sweden). Sweden also reported that the 
Prisons and Probation Service are obliged to report if they 
suspect that a child is being mistreated. In Germany, such 
an obligation on professionals to report has been noted to 
clash with physicians’ confidentiality obligations, though a 
new law – the ‘Bundeskinderschutzgesetz’, which came into 
effect on 1 January 2012 – aims to lay down a standard to 
address this.
In Poland, if the behaviour of the drug-dependent parent 
results in harm to the child’s health, the child has a right to 
compensation under the Civil Code, even if the actions 
occurred during the mother’s pregnancy.
(3)  See the EMCDDA website for information on treatment regimes in European countries.
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No precise information is available on how many drug users 
live with children in Europe. The only data that are available 
concern drug users entering treatment. This population, 
however, is only a partial representation of all drug users 
who live with children, and not all countries in Europe collect 
this information. The latest available data on those entering 
treatment for drug use problems in 26 European countries 
show that about one in ten clients (ranging between 3% and 
17%) entering treatment in 2010 lived with children (alone 
or with a partner, see Figure 2). Overall, 5% of all treatment 
entrants (or 40% of those who reported living with children) 
were single parents; on average, women were four times 
more likely than men to be single parents.
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Figure 2:  Percentage of all reported clients entering treatment for 
drug problems living with children
NB:  Data are for 2010 or most recent year available. Data for Poland 
refer to data from a pilot study; data for the United Kingdom come 
from its 2011 National report and refer only to England. For more 
information, see Table TDI-14 in the 2012 statistical bulletin.
Sources: Reitox national focal points.
Risks related to drug use in the family
Drug use is often a burden not just on the user, but also on 
other family members, including spouses, parents, siblings 
and children (Copello et al., 2005). Dependent children are 
especially affected – albeit differently at different ages – by 
a parent’s drug problem, since parents’ ability to rear, 
protect and care for their children, attend to their health, 
feed them and financially support them may be greatly 
diminished by their drug use. Furthermore, being 
preoccupied about drug supplies can compromise parents’ 
abilities to be consistent with their parenting and emotionally 
responsive to their children’s needs (Barnard and 
McKeganey, 2004). Drug use problems in families, however, 
express themselves in a range of ways, varying in intensity 
and duration, and children will exhibit different degrees of 
vulnerability and capabilities of tackling the stresses to 
which they are exposed (Velleman and Templeton, 2007). 
Below is a summary based on reports by national focal 
points, which reported an array of studies describing the 
potential harms that drug use may have on families.
Physical and mental health and other outcomes for the 
children are the results of a balance between risk and 
protective factors that operate and interact with each other 
at the level of the parent, the child and the environment. Risk 
factors may include genetic and biochemical factors, 
parenting, family coping styles, and violence within the 
family and in the surrounding environment. Protective 
factors, such as high levels of life skills, or attention, care 
and social support by another parent, family member, or 
social network, counteract the negative effect of risk factors. 
Based on the above, a model was developed by Hosman et 
al. (2009) showing the interconnection of risk and protective 
factors as they relate to mental health outcomes in general. 
While this model was not developed for drug use 
specifically, it can serve as a point of departure for the 
development and organisation of preventative and treatment 
interventions of problems in children of parents with a drug 
use problem, a psychiatric disorder or both.
Drug users living with children
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When present in a family setting, addiction problems are 
often not restricted to one drug-using parent, but may 
involve both parents or may span generations. Studies 
reported by the national focal point in Germany have 
found that, while alcohol dependence usually afflicts only 
one parent in a family, problem drug users 
disproportionately often have partners who are also 
dependent on drugs. Although parents may disapprove of 
their own drug use and discourage their children from 
using drugs, an Irish study found that they are usually not 
successful in transmitting these values to their children. This 
is demonstrated by statistics in, for example, Norway, 
where over half of drug users in treatment reported parents 
with a serious alcohol or drug problem – although this 
figure may be overstated given the nature of the study 
population. In addition, a study reported by the Danish 
national focal point has recently found that about a third of 
children who grew up with substance-using parents had 
substance use problems later in life. This study suggested 
that, in addition to the environment, genetic factors may 
also play a role.
Parenting problems are among those that affect children the 
most. Studies described in the German National report 
found that, compared with non-drug using parents, drug-
dependent parents are more prone to neglecting their 
children, and therefore children in families with addiction 
problems often need to assume parental responsibilities and 
tasks, such as running the household and taking care of 
younger siblings. The interaction between a drug-dependent 
parent and his or her child is often disturbed: studies from 
the Netherlands indicate that children are often neglected or 
abused, or they have low engagement with their parents. 
One major parenting deficiency reported by the Irish focal 
point is related to the ability and consistency of setting limits: 
at times parents use unwarranted discipline, while at other 
times they are overly permissive. This imbalance in the 
families places a large amount of stress on the children, 
especially if the mother is the one affected by the drug 
problem.
An array of studies in the United Kingdom assessed how 
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Figure 3:  A developmental model of trans-generational transmission of psychopathology
Source: Adapted from Hosman et al. (2009).
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ensure that their family life appears as normal as possible, 
drug-using parents often resort to ‘damage limitation’ 
methods, whereby they try to keep their drug taking secret 
from their children (Rhodes et al., 2010). They may, for 
example, try to avoid sleeping during the day, hide from 
their children when they have withdrawal, or hide their 
drugs and paraphernalia. Despite all these efforts by the 
parents, though, children are usually aware of their parents’ 
drug taking, and at earlier ages than the parents may think. 
The children, however, keep this knowledge to themselves; 
this points to the potentially high number of children who 
may be in need of support services that may not be visible 
to the appropriate service providers.
In Germany, the living circumstances of families affected by 
drugs have been described in a number of reports. These 
studies show that, compared with the general population, 
problem drug users generally have lower levels of education 
and occupational training, and higher levels of poverty and 
unemployment. As a result, the socioeconomic circumstances 
in which they bring up their children are less advantageous 
than of those who do not use drugs. In addition, children in 
families with addiction problems may experience 
emergencies and stays in hospitals, the arrest of parents, 
suicide attempts and deaths more frequently than other 
children. The uncertain living circumstances, poor housing 
conditions, poor nutrition and a socially constrained 
environment have a negative impact on the physical, 
psychological and social development of the child.
Conduct disorder and other psychopathological symptoms 
are some of many ways how children externalise problems 
in dysfunctional drug-using families. A study in Austria 
among children aged three to six years old in families with 
drug-using parents found that a third had signs of 
developmental disorders, another third showed 
psychopathological symptoms and 14% exhibited attention 
deficit disorder. Of all the children, about a third are 
expected to have problems at school due to their conduct 
disorders, while another third will have school problems due 
to their developmental disorders. Academic progress of such 
children, as reported by an Irish study, may be further 
hindered by poor attendance and low levels of parental 
involvement. According to a Danish study, one in ten of the 
children who live with parents with substance use problems 
are diagnosed with mental disorders and two in five have 
physical or mental health problems.
Children of drug-using parents, Ireland further reports, may 
live under circumstances where their vulnerability is difficult 
to detect; for example, young carers looking after parents 
with drug or alcohol addictions. In such cases, families do 
not want people to know the circumstances within which a 
child acts as caretaker; they may fear that the child will be 
taken away by social services. In Austria, for example, a 
study found that in families affected by drug use a third of 
the children were moved to foster parents at a very early 
stage, another third remained with their mothers at first and 
were transferred to another caregiver within the first few 
years of infancy, and a third stayed with their mothers. 
Polydrug-using mothers were more likely to have their 
children taken away. While living with foster parents may 
seem to be favourable for the positive development of 
children, the stabilisation of the biological family through 
adequate treatment, care and support, and the increase of 
social network ties with non-drug using friends and 
extended family are always the best solution for both 
children and parents.
Responses targeting drug-using parents
An array of interventions is available for drug-using parents, 
ranging from addiction treatment and integration of their 
children in the biological families; through provision of or 
referral to care services, psychosocial support, prevention 
Resilience
In psychology, resilience refers to an individual’s tendency 
to cope with stress and difficulties. Resilience may help a 
person ‘bounce back’ to a previous state of normal 
functioning, or people may use the experience of a stressful 
situation to function better in the future (Masten, 2001). 
Resilience can be considered a process rather than a trait 
of a person. This is an important concept to explain how, in 
spite of the exposure to many risks, children growing up in 
families with problems can become well-functioning adults 
(Velleman and Templeton, 2006). The study of resilience 
emerged about 40 years ago when some scientists 
studying high-risk groups found that many children were 
developing well in spite of their underprivileged 
environments. Resilience is a natural tendency for some 
individuals, but it can also be promoted through specific 
interventions, as many studies have proven. These 
interventions, for example, connect children with confidants 
outside their problem families, because positive 
relationships with competent adults can improve the 
resilience factors, or involve children in meaningful 
pastimes. Helping children become aware of their problems 
increases their desire to overcome those problems. 
Teachers, social workers and other adults in their 
environment should create a stimulating environment where 
children’s talents can evolve despite all their difficulties. 
Such coaching fosters resilience and improves social 
functioning (Newman, 2002).
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interventions and empowerment; to skills building. These 
types of interventions are often offered by comprehensive 
prevention programmes, while smaller programmes may 
specialise only in one type of response. The examples 
mentioned below are programmes reported by the national 
focal points, and may not be an exhaustive list of those that 
run in various EU countries.
Integration of children in their biological families
Many drug-using parents shy away from seeking treatment 
or care, because they fear that their children may be taken 
away from them. While at times these fears may be well 
founded, in the majority of cases authorities support 
drug-using parents in their efforts to seek care and treatment 
in order that children can stay with their biological parents 
in an improved, healthier environment. However, even when 
children are taken from their drug-using parents, they are 
often placed in families of close kin. For example, the wide 
range of social services provided by the Bulgarian 
foundation ‘For Our Children’ includes services promoting 
the reintegration of babies and children into their biological 
families, and there is an emphasis on extended families 
when placement in foster families or care is necessary. One 
of the founding principles of the Lichtblick project in 
Frankfurt, Germany, is that it is in the best interest of the 
children to avoid being removed from the custody of their 
biological parents. The comprehensive services provided by 
the project aim to empower drug-using parents to create a 
healthy physical and mental environment for their children.
In January 2008, a pilot family drug and alcohol court 
(FDAC) was set up in London to address the specific needs 
of drug-using parents and thus improve outcomes for their 
children (Harwin et al., 2011). It was the first court of its kind 
in England and Wales, and consisted of a rehabilitation 
programme for drug-using parents whose children are 
subject to care proceedings, and was led by a judge. In the 
final evaluation report, it was shown that 39% of children in 
areas that were served by the FDAC stayed with the family, 
in comparison with 21% of children in families who were 
subject to normal care proceedings. There was also a 
positive difference reported in the proportion of mothers 
who had stopped substance misuse (48% compared with 
39%). A greater reduction in substance use was also 
reported among fathers in the evaluation (39% of those in 
the FDAC group compared with one of the 19 fathers in the 
other group).
The Health Service Executive (HSE) in Ireland has developed 
a pilot project with a family-oriented approach that is 
expected to reduce the number of children who need to 
leave their families to be cared for in alternative forms of 
care. In addition, the HSE provides a full range of support 
services to both parents and children, including therapeutic 
work, parent education programmes, home-based parent 
and family support programmes, child development and 
education interventions, youth work and community 
development. The evaluation of the Families First project in 
north-east England showed that parents at risk of losing their 
children can successfully change their lives such that the 
children can remain safely in the family home. The 
availability of kinship care, usually provided by 
grandparents, was an important factor in preventing 
children from being taken into care (Templeton, 2011).
Family-based residential treatment programmes
Inpatient residential treatment programmes that specifically 
cater to the needs of families exist in some Member States. 
For example, the therapeutic community Sananim in the city 
of Karlov (Czech Republic) has provided treatment to 
altogether 115 dependent mothers and their 117 children 
since 2001. The Belgian organisation Trempoline developed 
the Kangaroo project with the objective of supporting 
women in their role as mothers. During the daytime, while 
mothers in this therapeutic programme are engaged in 
activities (e.g. therapeutic community and social 
reintegration), their children attend nursery school, 
kindergarten or school classes, depending on their ages. 
The inpatient treatment clinic De Lage Kamp in the 
Netherlands has been serving addicted parents and their 
children (up to age 12) for more than 15 years. Treatment is 
offered to up to nine families at a time for the duration of 12 
months on average, with detoxification during the first four 
weeks. Parents participate in group sessions and receive 
individual counselling, and children are in day care 
engaged in educational activities and games. A high-
threshold programme in Slovenia called Projekt Človek 
Society houses three families (mothers or fathers and their 
children) at a time. This inpatient social rehabilitation and 
The Exchange on Drug Demand Reduction 
Action (EDDRA)
The Exchange on Drug Demand Reduction Action (EDDRA) 
is an online inventory of projects collected by the Reitox 
national focal points. It provides a broad overview of 
evaluated interventions in Europe. Some of these projects 
addressing pregnant women, children and drug-using 
parents are described in the response sections of the 
present publication. The EDDRA collection is available at 
the Best practice portal.
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addiction treatment programme teaches parents skills 
related to parenting and improving the relationship with 
their children. A nationwide network of inpatient facilities in 
Finland (the Federation of Mother and Child Homes and 
Shelters) has been offering treatment and care to drug-using 
mothers (and, to a lesser extent, fathers) and their children 
since the late 1990s. Several family inpatient institutions 
exist in Norway as well: a national study from 2005 
showed that 93% of the children were under the age of 
three years, and 25% of them were born while the mother 
was already staying at the institution.
The Coolmine Therapeutic Community in Ireland is the only 
residential service in the country where children of primary 
school age can live on site with their mother, allowing the 
mothers to receive the support they need as their children’s 
personal development is strengthened through specialist 
counselling and child welfare initiatives. The Federation of 
Mother and Child Homes and Shelters in Finland runs a 
national specialised treatment system known as Pidä kiinni 
(Hold tight), consisting of seven mother and child homes 
around the country. To date, the Pidä kiinni homes and 
service units have rehabilitated about 1 500 families. The 
service reaches some 250 families annually, of which about 
100 are referred to mother and child shelters and about 150 
to outpatient services. In the Lithuanian public institution 
TC-Laisva valia, up to 10 substance-using women may get 
long-term psychological care and social rehabilitation 
services together with their little children. The ‘Eltern-Kind-
Haus’ (‘parent–child house’) in Boeddiger Berg, Germany, is 
a special service where drug-using parents live together with 
their children and receive advice and help regarding 
child-raising questions and support in organising everyday 
family life.
Provision of or referral to care services
Parents with drug problems and their children need 
ongoing care. This includes follow-up by case managers of 
those who are involved in prevention programmes with the 
aim of providing ongoing counselling to prevent drug use 
and encouraging a healthy lifestyle. Some may require 
clients to return to the programme that they participated in, 
while others provide home visits. Specific help offered to 
clients may include crisis intervention, legal help with 
issues related to drug use, and childcare while they 
participate in programme activities. Obviously, not all 
programmes may be comprehensive enough to offer all 
services that this target population may need. They often, 
therefore, provide referrals to other services, or encourage 
service utilisation.
The Kiddo Project in Belgium helps parents become aware 
of how their current or past drug problems may affect their 
children, informs them about other services available and 
encourages them to make use of those services. In addition 
to referring mothers to facilities in the area of child and 
youth welfare services, the ‘Liliput – Mutter + Kind’ service 
offers individual counselling to mothers and children, 
childcare and leisure time activities in Nürnberg, Germany. 
In Kassel, Germany, KIDS reaches out to expectant drug 
users and mothers with drug problems and connects them 
with social and health services. Päiväperho (Butterfly) in 
Finland links substance-using pregnant women and mothers 
of small children with child welfare services, substance use 
services, maternity clinics and family counselling clinics, in 
addition to providing low-threshold services.
Since 2000, a crisis intervention service called Option 2 has 
been running in Cardiff and the Vale of Glamorgan, Wales. 
Staff work intensively with two or three families for up to 30 
The role of the family in treating drug addiction
Evidence shows that involving family members in the 
treatment of their relatives affected by drug addiction is 
important for at least two reasons: to alleviate the 
symptoms of stress and their consequences in family 
members, and to improve the effectiveness of treatment 
(Orford et al., 2010). Copello and colleagues (2005) 
identified three main types of family-based interventions, 
and presented evidence to support the effectiveness of all 
three types: those aimed at the involvement of the family to 
promote the entry of the substance user into treatment; 
interventions which involve the family in the treatment itself; 
interventions aimed at supporting the family members. 
Other reviews have shown that family-oriented interventions 
also decrease behaviours and situations that facilitate 
substance use, by modifying the emotional environment 
linked to substance use. A review study in Germany that 
assessed services aimed at drug-using parents identified a 
systematic family-oriented approach as an important 
conceptual element in work with families with addiction 
problems. Group services (support groups, individual 
counselling, case counselling, weekend seminars, crisis 
intervention and parent training courses), public-relations 
work (awareness of services), administration (planning of 
resources) and supporting services (childcare while parents 
take part in activities or family seminars) are also key 
elements that contribute to the success of the programmes. 
Initiating contact with help agencies is often difficult for 
drug-using parents; feelings of embarrassment and shame, 
and fear of losing their children were identified as major 
barriers to seeking care. Outreach and referral by other 
– often non-drug-related – services may help parents 
overcome these barriers.
19
Pregnancy, childcare and the family: key issues for Europe’s response to drugs
hours a week over a four-week period, with follow-up visits 
at one, six and twelve months post intervention. Booster 
sessions are available to respond to a crisis or to help 
parents reinforce their coping skills. Parents are asked to 
develop goals to reduce risks to their children and to identify 
behavioural changes which will prevent their child from 
being taken into care by social services. Examples of goals 
include drug or alcohol abstinence; improved family 
relations; developing improved routines for children; dealing 
with domestic violence; and managing children’s behaviour. 
Several similar interventions which target families with 
substance use problems using the Option 2 model have 
been developed across the United Kingdom, but provision is 
not provided on a national basis.
A multidisciplinary social work team, including community 
care and probation professionals, is available at the Drug 
Treatment Centre Board in Dublin, Ireland, focusing on 
family support (including child welfare), advocacy, group 
work, writing reports and attending inter-agency meetings. 
A children’s playroom provides stimulation and a safe and 
supportive child-centred setting for children aged between 1 
and 14 years, who accompany their parents or guardians to 
the clinic. They also offer advice and support to parents who 
may have childcare concerns. The Ballyfermot Advance 
Project in Ireland subsidises childcare costs in order to 
facilitate treatment access to drug-using parents.
Social work at police stations is an important element of 
responses in Finland. It involves responding to situations that 
emerge in the course of police work involving children, 
young offenders, people experiencing family and domestic 
violence, mental health patients, drug users and other 
people undergoing acute crises.
Psychosocial support
Several activities provide psychosocial support for 
recovering drug-using parents. Psychotherapy, psychosocial 
care, and support groups with activities to learn healthy 
expression of emotions are aimed at minimising the 
complications related to drug use. Several programmes offer 
services facilitating social reintegration and rehabilitation.
The Welsh programme Integrated Family Support Services is 
a multiagency service which provides targeted support to 
families where there are concerns regarding child welfare 
and parental substance misuse (drugs, alcohol or both). It is 
a family-centred approach to services which provides early 
intervention in addition to crisis management. The aim is to 
provide intensive support to improve parenting capacity as 
well as social service intervention and to help bridge the 
gaps between child and adult services by protecting 
vulnerable children, while at the same time helping parents 
to develop new skills. Four ‘pioneer’ areas in Wales 
adopted the scheme in late 2010, and it is reported that 
some early successes in preventing children being taken into 
care have been observed. These areas were to be evaluated 
in 2011, and following this it is expected that the programme 
will be rolled out nationally. The evaluation is due for 
publication in 2012/13.
An array of services in Germany provides psychosocial 
support to drug-using parents and their children. 
Regenbogen, an inpatient aftercare programme in Germany, 
provides abstinence-based support, counselling and 
assistance to parents with substance use problems. The 
HiKiDra project in Kiel offers comprehensive social 
counselling for parents, and support groups not only for 
mothers, but also for pregnant women, children and 
adolescents. The ‘Bella Donna’ drug-counselling office has 
been offering services to women and girls in Essen since 
1992. Its training programme MUT! helps mothers who use 
drugs or are in substitution treatment, and their children, by 
providing support, suggestions and practical help in the 
everyday chores of raising children. Childcare is available 
while mothers attend group meetings.
Empowerment and skills building
Parents who are seeking to recover from drug addiction 
benefit substantially from acquiring and strengthening skills 
that enable them to forge a strong family. Building 
parenting skills – including setting limits for their children, 
planning and organising the household, and planning the 
children’s education – are a main goal of therapeutic 
programmes. These include being aware of the parent’s 
addiction, learning how to deal with real-life family 
situations and acquiring everyday practical skills. A key 
aspect is building family coherence by planning family 
leisure time and fostering the parent–child relationship. 
Skills-building activities related to interpersonal skills, 
communication, coping, problem solving and decision 
making are also often part of therapeutic work for parents 
with drug problems.
The Ana Liffey Drug Project in Ireland aims to promote and 
support high-quality parenting and to enhance the quality of 
life for children whose parents use drugs. SAOL is a 
community-based educational and rehabilitation day 
programme for women in treatment for drug addiction. It 
provides a full-time childcare facility and early education 
programme for their children: SAOL Beag (Little SAOL) 
Children’s Centre. Using an individualised curriculum and 
approach to work with the children, the programme seeks to 
identify each child’s interests, strengths and learning goals 
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and to plan activities and learning experiences for the child. 
An integral part of this service is to work in partnership with 
the parents. Another key element is the relationship the 
children have with the adults who work with them: the staff 
are qualified and experienced in dealing with children and 
aim to form strong, caring relationships with the children.
A special programme in Denmark called ‘Dag og 
Døgncenteret’ (the Day Care and Inpatient Centre) is an 
inpatient programme that places the mother (or parents) and 
the child together in a foster family under special terms and 
conditions. In this system, the parents are not allowed to take 
the child with them if they unexpectedly leave the foster 
family or experience recurrence of their drug use. In 
Denmark, other inpatient institutions exist that do not 
specifically target drug-using parents with children, but are 
aimed to help families with any psychosocial problem or a 
risk of neglect. The ‘1-2-3 Lass!’ (1-2-3 Go) project in 
Luxembourg targets pregnant women and mothers with 
children under two years of age. It started as a pilot project 
in 2007 as a collaboration between the ‘service parentalité’ 
and the National Drug Addiction Prevention Centre, with the 
aim to strengthen and improve the parenting skills of 
participants.
The Polish government sponsored a prevention programme 
in 2010 entitled ‘New Beginning’, targeting drug-dependent 
mothers and pregnant women. The programme featured 
support groups and parenting classes. The aims were to 
improve the participants’ knowledge and skills regarding 
conflict solving, coping, positive thinking and leisure time 
activities; to manage the child’s development; to improve the 
parent–child relationship; and to promote parenting skills. 
Besides psychological and health matters, some classes 
were devoted to legal issues.
Responses targeting drug users’ children
Children in families affected by drug use may have different 
needs, based on a variety of factors. For example, children 
who have drug-using parents, but who do not show signs of 
maladjustment or developmental difficulties, may need 
different interventions from those children whose behavioural 
problems are a reaction to the parent’s drug problems. On 
the other hand, the drug use habits of the parents may be 
hidden from outsiders, with the result that the potential 
maladjustment of the child may not be responded to 
appropriately. Despite the potential difficulties concerning 
identifying children who are raised in families affected by 
drug use, an array of interventions is available for them, 
ranging from integration of children in their biological 
families, through provision of care services, psychosocial 
support and prevention interventions, to skills building.
Care services
In some European countries, services targeting children of 
drug users are historically part of the welfare services. For 
example, in Prague, the Centre for Children, Young People, 
and the Family has been serving families affected by alcohol 
and drug use since 1967. Their programmes for children 
include special counselling and child welfare services with 
the aim of providing children with a safe space where they 
can strengthen their personal development. The centre has 
also provided research data for studies assessing the effects 
of parents’ alcohol use on children.
In Portugal, the Centre of Integrated Responses performs the 
assessment and screening of children in families with 
addiction- or alcohol-related problems, youth at risk or 
young people with alcohol or drug problems. In 2010, 
3 920 adolescents were attended to, and 20 referrals and 
750 appointments of family support were made. 
Appointments, often through partnerships with other entities, 
are also available to parents, teachers and members of the 
educational community.
Often care services for children are not specialised in drug 
use, but cater to the needs of families with a range of mental 
health problems. The ‘Squeak Says the Mouse’ project in the 
Netherlands, for example, offers support in low-economic-
status neighbourhoods for children between the ages of four 
and eight who have a parent with a psychosocial, mental 
health or substance use problem. The aim is to 
counterbalance the combination of parental factors and the 
high-risk environment and keep the children from developing 
problems similar to those of their parents. A pre–post 
evaluation showed a significant decrease in emotional 
problems and a significant increase in positive social 
Internet-based prevention interventions for 
drug-using parents
Several programmes use alternative means, such as email, 
phone or the Internet, to reach families affected by drug 
use. An Internet-based intervention called www.
kopopouders.nl (‘cheer up, parents’), based in the 
Netherlands, is the online version of a face-to-face course. 
The contents are designed to support parents with a 
psychiatric disorder or addiction problem on issues related 
to the upbringing of children. Professionals from mental 
health institutes coach the parents in online group courses, 
and through chat and email. In 2009, the site reached 
almost 40 000 parents. A pre–post evaluation showed a 
significant decrease in parenting problems among 
participants.
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behaviours among participating children. Two projects in 
Austria (the Jojo project in Salzburg and KIPKE in St Pölten) 
target children of parents with psychiatric illnesses. Children 
participate in individual and group sessions where they 
learn skills that help them cope with their parents’ illness.
Psychosocial support
In Belgium, the project ‘La Brique’ implemented by the AVAT 
institution is a place where children aged 12–17 who have 
drug-using parents can receive psychosocial support and 
express their feelings in a creative way. In Germany, the 
national model project ‘Trampolin’ focuses on children in 
families with addiction problems and seeks to strengthen 
their self-image and ability to solve problems. For example, 
specific group activities aim to inform participants about 
drugs and alcohol, remove taboos on the subject of 
addiction and teach strategies that help them cope with 
stress. The project is supported by the German Centre for 
Addiction Problems of Children and Youth (Deutsches 
Zentrum fuer Suchtfragen des Kindes- und Jugendalters) and 
the German Institute for Research on Addiction and 
Prevention (Deutsches Institut fuer Sucht- und 
Praeventionsforschung), and is carried out at sites in all 16 
German Laender. The KiSEL project in Loerrach focuses 
mainly on children and adolescents from families with 
addiction problems, but it also provides parenting support 
counselling services for parents. In the Netherlands, 
face-to-face support groups for children of parents with a 
psychiatric disorder and children of addicted parents aim to 
increase the social well-being of the children by increasing 
their resilience, thereby diminishing their likelihood of 
developing psychopathology. An effectiveness study is 
currently ongoing in the age group 8–12 years. A large 
number of municipalities in Sweden have support groups for 
children whose parents have substance use problems. 
During these group activities, children share their 
experiences with others who live under similar 
circumstances. No evaluations, however, have assessed the 
effectiveness of these support groups in Sweden.
Empowerment and skills building
‘Strengthening families’ is a family-based intervention, 
developed in the United States two decades ago, that 
targets parents with a drug or alcohol problem and their 
children. The intervention aims to increase the social 
capacities, communication skills and self-confidence of 
participating children, and addresses several problems, not 
only those related to drug use. Adapted versions of 
Strengthening families have been implemented in at least 11 
European countries (4). A German project called ‘Jonathan’ 
has been available for children and youth from families with 
addiction problems in Erfurt since 2006. Services include 
informing different age groups about specific topics relating 
(4) Germany, Greece, Ireland, the Netherlands, Poland, Portugal, Slovenia, Sweden, the United Kingdom, Norway.
Internet-based interventions for children of 
drug-using parents
Several European countries reported on Internet-based 
responses for children with drug-using parents, taking 
advantage of the computer literacy of younger generations 
to reach the target group. The ‘Kidkit‘ project in Germany is 
a low-threshold, Internet-based service available since 
2002 for children and adolescents who live in families with 
addiction problems and/or experience domestic violence, 
providing information about topics such as ‘addiction and 
family’ and ‘violence and family’. The project also offers 
free and anonymous online counselling.
The Netherlands-based Kopstoring is an interactive website 
for adolescents and young adults aged 16–25 who live 
with drug-using parents. The site, which receives about 
10 000 unique visitors each month, includes information 
pages, a panel discussion, email services and a chat box, 
and aims to strengthen the coping skills of adolescents and 
young adults in order to prevent and alleviate behavioural 
and psychological problems. A process evaluation showed 
significant decreases in parentification – whereby a child is 
obliged to act as parent to their own parent – and in 
negative feelings towards the home situation. The website is 
currently ongoing a randomised controlled evaluation and 
a cost-effectiveness assessment. Another Dutch site, 
Survivalkid is a members-only site for youngsters aged 
12–24 who have parents or siblings with a psychiatric 
disorder or substance use problem. The site provides 
information on psychiatric disorders and addiction, has a 
chat function with peers, and includes a chat and email 
facility with a ‘survival coach’.
The DrugLijn project in Belgium provides general information 
on addiction, including suggestions to answer the question 
‘What to do if your parent(s) use drugs?’ (*). In Sweden, the 
Swedish Council for Information on Alcohol and Other Drugs 
has developed a web-based self-help programme, 
Drugsmart, for children of substance-using parents. The 
programme will be evaluated by researchers at the 
organisation STAD (Stockholm Prevents Alcohol and Drugs).
(*)  Websites dealing with the issue of drug-using parents may exist in 
other countries as well.
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to addiction problems, leisure time activities, pedagogical 
assistance and social skills development. Other services 
have also been available since 2011, including consultation 
days for parents, children and institutions. At times, help is 
provided not only to families affected by drug use, but also 
to families with a range of other mental health problems.
Policy and legal frameworks concerning 
drug-using parents and their children
Legal framework at international level
The main international laws governing illicit drugs are the 
UN Conventions of 1961, 1971 and 1988. The first two 
make no mention of young people. The preamble of the 
1988 Convention Against Illicit Traffic in Drugs expresses 
deep concern for the fact that children are used as a 
consumer market and for drug distribution, and in Article 
3(5) it mentions the victimisation of minors or distribution 
near schoolchildren, for example, as aggravating supply 
offences. Nevertheless, there is no express mention of 
children of drug users.
However, the following year (in November 1989) the UN 
Convention on the Rights of the Child was signed. Article 33 
states:
States Parties shall take all appropriate measures, 
including legislative, administrative, social and 
educational measures, to protect children from the illicit 
use of narcotic drugs and psychotropic substances as 
defined in the relevant international treaties, and to 
prevent the use of children in the illicit production and 
trafficking of such substances.
The preamble states that the child ‘needs special safeguards 
and care, including appropriate legal protection before as 
well as after birth’. As there is no mention of from whose 
illicit drug use the child should be protected, this has been 
interpreted as meaning that states should protect children 
from drug use within the family (Barrett and Veerman, 2012). 
It may be read together with Article 24, which gives the 
right to antenatal and postnatal care, and therefore may 
include substitution treatment for opioid-dependent people, 
and may also be considered as supporting parenting skills.
Legal framework at European level
At the European level, there is again no specific law 
applying to the children of drug users. Nevertheless, the 
issue of removing children from families may be governed 
by the right to family life. Article 8 of the European 
Convention on Human Rights states:
1.  Everyone has the right to respect for his private and 
family life, his home and his correspondence.
2.  There shall be no interference by a public authority 
with the exercise of this right except such as is in 
accordance with the law and is necessary in a 
democratic society in the interests of national security, 
public safety or the economic well-being of the 
country, for the prevention of disorder or crime, for 
the protection of health or morals, or for the 
protection of the rights and freedoms of others.
In interpreting this, states are allowed some discretion, 
known as the margin of appreciation. This will differ 
according to context but is particularly wide in the area of 
child protection (Kilkelly, 2003). Nevertheless, it has been 
established by the court that a family life will always include 
the relationship between a mother and child, even when 
there is no marriage, no cohabitation, or only potential 
family life even if it has not been established (for example, if 
a child was removed from a parent at birth) (Kilkelly, 2003). 
As the well-being of the child is paramount, the return of the 
child to the parents should always be considered; without 
measures to prepare for the child’s return to his or her 
parents, the implementation of a custody order may be 
damaging to the child (Conrod et al., 2010). This was 
reported as a basic principle in Belgium, Latvia, Slovenia 
and Slovakia. In the Czech Republic, one of the objectives 
of the national action plan on caring for vulnerable children 
is to reduce the number of children in institutional care, while 
the Irish Child Care Act, 1991, aims to avoid the use of care. 
If disagreements between parents or authorities occur, the 
child has a right to be informed of proceedings and to 
express its opinion, according to the European Convention 
on the Exercise of Children’s Rights 1996.
Legal framework at national level
Given the very specific focus of the Convention on the Rights 
of the Child on illicit drug use, as it was drafted 20 years 
ago, it is perhaps a sign of development of the public health 
paradigm in the field of substance use that most countries 
appear to address the problem in a more general frame of 
harm to the child that may be caused by addiction to any 
substance, including alcohol, or by belonging to a certain 
‘risk group’. No country in Europe reported that drug use in 
itself was a reason to remove the child from the parent. 
Perhaps comparably, few countries reported that the 
children of drug-using parents were a specific target group 
in the national drug strategy or action plan. In Portugal, 
there are several mentions in the 1999 National Strategy 
and the 2005–12 National Plan. The 1999 document 
identifies the difficulty of finding places in therapeutic 
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communities and specialist treatment programmes for 
pregnant women and those with children, and requests 
attention to prevention activities for the children of addicts. 
These are developed in the 2005 plan, and have resulted in 
guidelines for children of drug users (2010), while guidelines 
for monitoring pregnant women are being drafted. The 
Luxembourg National Drug Action Plan refers to the 
‘parental service’, which follows judicial measures under the 
Child Protection Act, as a priority 1 project that should be 
further developed. In Austria, which has drug or addiction 
policy papers in each of the nine provinces rather than one 
national document, the children of addicted parents are 
explicitly mentioned in the policy papers in four provinces as 
target groups for prevention and/or treatment services (in 
fact the 1999 Drug Policy Programme of Vienna points to 
good results from a hospital project, indicating that this was 
a focus early on). In Ireland, the National Drugs Strategy of 
2001 considered childcare facilities in treatment centres, 
and the new strategy of 2009–16 identified the children of 
drug users as a ‘group at risk’ and called for considering 
ways to address the needs of the children of problem drug 
users. The current UK Drug Strategy of 2010 focuses on 
early intervention for vulnerable young people, in which it 
includes children of drug users; in Northern Ireland, the rate 
of children on the child protection register due to parental 
drug use is a key indicator in the Children Services Plan 
2008–11, rather than the drug strategy. Within the wider 
substance use framework, the 2011 Swedish strategy for 
alcohol, narcotic drugs, doping and tobacco policy contains 
an interim target for its second objective that fewer children 
should be born with damage caused by those substances. 
However, most countries reported that the children or 
parents would be covered by more general terms in the 
national drug or addiction strategy documents without 
specific mention.
Besides treatment, childcare facilities may also be an issue 
for drug-using parents, though there was little focus reported 
on this. In 2001, the Irish National Drugs Strategy called for 
consideration of how to integrate childcare facilities with 
treatment and rehabilitation centres, and provision in 
residential treatment settings. Four years later, it was 
considered that full-time childcare facilities within an 
addiction setting may lead to further stigmatisation of the 
children of drug users, and that more appropriate services 
should be provided.
Given the potential for conflicts between laws and 
strategies, it is interesting to note calls and efforts made in 
coordination in this area. In Germany, from January 2012, 
the law to strengthen protection of children aims to provide 
a legal foundation for binding network structures for child 
protection, where conflicts have occurred in the past. The 
Irish National Drugs Strategy 2009–16 called for facilitating 
closer engagement between child, outreach and drug 
services at a local level. The Ministry of Family in 
Luxembourg set up a ‘national office of childhood’ in 
December 2008. Youth care in the Netherlands is being 
revised, after the multiplicity financing structures was 
identified as a major barrier; there will be one financing 
structure and central coordination of financing at the level of 
the municipalities, committing collaboration between all 
professionals. Austria reported good results in care and 
support for pregnant drug users and their children, from a 
service providing interdisciplinary cooperation between 
hospitals. The 1999 Portuguese drug strategy declares the 
importance of coordination of programmes for pregnant 
addicts with maternity departments and obstetrics services. 
In Sweden, the 2011 alcohol, narcotic drugs, doping and 
tobacco strategy has set targets for a clearer division of 
responsibilities between the principals for substance use and 
dependence care. In the United Kingdom, statutory Local 
Safeguarding Children Boards (Child Protection Committees 
in Scotland) are made up of representatives from across key 
children’s services and should ensure regular sharing of 
information and local multiagency working.
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Drug users who aim to stabilise their lives face several 
challenges, including access to treatment, stabilisation of 
their drug use, social reintegration and referral for health 
problems other than drug use. Drug users who have 
children, however, constitute a special subgroup, because in 
addition to their concerns related to drug use in general, 
they also have additional needs, such as childcare while 
they are in treatment and assistance with issues related to 
parenting. Furthermore, the legal protection and the right of 
their children to grow up in their own family may be 
threatened with the possibility that the children can be 
removed if child protection services consider their 
environment dangerous to their well-being. This Selected 
issue gives a broad overview, based on reports by EU 
Member States and Norway, on the extent of and available 
responses – interventions, laws and policies – to the 
problems of pregnant drug users and families that are 
affected by problem drug use.
National reports indicate that legislation in Europe strives to 
keep the family united rather than take away the children. 
No country reported that drug use was a reason per se to 
remove the child from the parent. Legislation applying to 
pregnant drug users or to children before birth facilitates 
eligibility to treatment in many countries. In addition to 
legislation, a variety of interventions – many of them 
evidence-based – have been developed in European 
countries to help pregnant drug users and addicted parents 
and their children. For example, the majority of treatment 
interventions for pregnant women follow the evidence of 
providing substitution treatment to those dependent on 
opioids. Furthermore, to ensure that pregnant drug users 
receive proper and timely care, some countries organise 
outreach services and referral systems, and offer 
multidisciplinary comprehensive programmes during and 
after pregnancy, and therapeutic communities where 
recovering parents and their children can remain together. 
Interventions responding to the needs of drug-using parents 
and their children include measures enabling the children to 
stay with their biological families, family-based interventions, 
provision of or referral to care services, psychosocial 
support, empowerment and skills building. Internet-based 
prevention programmes are also available, especially for 
adolescents and young adults with drug-using parents, a 
target group that often still lacks appropriate interventions.
Data on the prevalence of drug use among pregnant 
women is not available for most European countries, so 
programmes aimed at helping pregnant drug users may not 
be aware of the size of the target group. In addition, it is 
unknown to what extent families affected by drug use are 
reached by existing programmes. National reports, 
however, indicate that coverage may be small or vary 
substantially by country, and that the viability of some of 
these programmes may be questionable. There are several 
factors that may contribute to this situation. First, a shortage 
of appropriate and available interventions at organisations 
that may cater for the needs of problem drug users and 
their families is often combined with a lack of policy 
support. Second, reaching the target group may be difficult. 
For example, several countries reported that a number of 
problem drug-using parents are not in treatment, and their 
children therefore may not be reached by addiction care. 
When in treatment, some clients may not disclose that they 
are parents. It has also been reported that children of 
clients in addiction care may not be targeted systematically, 
and that problem drug users may shy away from contacting 
such services because of their fear of stigmatisation 
surrounding drug addiction and mental disorders, and their 
fear of losing their children.
Those treatment services that exist may have several 
impediments that prevent them from increasing their 
coverage. For example, a potentially general issue 
reported by Finland relates to public funding: as drug 
treatment services are often dependent on funding from 
local or government authorities, budget cuts resulting from 
financial crisis may have negatively affected, among other 
things, the functioning of interventions and services 
targeting drug users with children. Diminished funding may 
have led to a loss of treatment places, an insufficiency of 
medications, a decrease in the variety and diversity of 
services, and the eventual closure of such services – to 
name just a few. As recovering from substance use and 
problems related to it may be lifelong processes, securing 
long-term government or other funding is an essential 
attribute of prevention efforts.
Conclusions
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In light of the above, continuous monitoring, especially 
identifying the size of the target population, might be 
helpful to better understand the issues, needs and potential 
solutions related to drug-using pregnant women, and drug 
users and their children. Identification and promotion of 
exchange of best practices will support countries in setting 
their goals and planning their responses. Where needed, 
accessibility and coverage of treatment should be 
increased, especially for pregnant drug users. Removing 
barriers to seeking treatment, including lack of childcare 
and fear of legal consequences, might further help this 
target population. Evidence-based family interventions 
should be further promoted. Appropriate interventions that 
strengthen the resilience of children can also help prevent 
children of drug users from becoming drug users 
themselves. The variety and coverage of appropriate 
preventative interventions based on such approaches still 
have room for improvement, as has the evidence base for 
interventions for pregnant drug users, drug-using parents 
and the children of drug-using parents.
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